When was Kelonia founded?

Kelonia was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Kelonia located?

Kelonia is headquartered in Boston, United States.

How many employees does Kelonia have?

As of May 31, 2026, the latest employee count at Kelonia is 74.

Is Kelonia a funded company?

Kelonia is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 28, 2022.

How much is Kelonia worth?

The last known valuation of Kelonia was $***** as of Apr 21, 2026.

When was the latest funding round of Kelonia?

Kelonia's latest funding was a $***** Series A round on Apr 28, 2022, with participation from 3 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.72B in funding in 2026 to date.

Where does Kelonia rank among its competitors?

Kelonia ranks 312th amongst 3465 active competitors, of which 1204 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Kelonia?

Kelonia's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Kelonia - 2026 Company Profile, Team, Funding & Competitors

Q: Is Kelonia an acquired company?

Kelonia got acquired by Lilly on Apr 20, 2026.

Company Details

Developer of medicines to treat autoimmune and inflammatory conditions. The company is developing a portfolio of therapeutic indications for tibulizumab, crebankitug, and torudokimab, with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders.

Website: keloniatx.com
Email ID: *****@keloniatx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Boston, United States

Stage

Acquired

Total Funding

$50.3M in 1 round

Latest Funding Round

Series A, Apr 28, 2022, $*****

Last Known Valuation

$***** as on Apr 21, 2026

Investors

Venrock & 2 more

Ranked

312^th among 3465 active competitors

Employee Count

74 as on May 31, 2026

Similar Companies

BeiGene & 1061 more

Exit Details

Acquired by Lilly (Apr 20, 2026)

View Kelonia's full profile

Kelonia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kelonia Therapeutics, Inc. CIN: 853729141 , Belgium, Active	Dec 31, 2020	-	59 (As on Dec 31, 2024)	-

Kelonia got acquired by Lilly on Apr 20, 2026 at an acquisition amount of $*****.

Click here to take a look at Kelonia's acquisition in detail

Kelonia has raised a total funding of $50.3M over 1 round. Its latest funding round was a Series A round on Apr 28, 2022 for $*****. 3 investors participated in its latest round. Kelonia has 3 institutional investors.

Here is the list of recent funding rounds of Kelonia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2022	5005420	Series A	3010734	6613930	8703757	8253866

Access funding benchmarks and valuations. Sign up today!

View details of Kelonia's funding rounds and investors

The founders of Kelonia is Michael Birnbaum.

Here are the details of Kelonia's key team members:

Michael Birnbaum: Co-Founder of Kelonia.
Contact Info: 1 email address

View details of Kelonia's Founder profiles and Board Members

Kelonia's employee count trend

Kelonia has 74 employees as of May 26. Here is Kelonia's employee count trend over the years:

Uncover Kelonia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kelonia include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kelonia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	Khosla Ventures, True North & 23 others	71/100
312th	Kelonia 2021, Boston (United States), Acquired	Developer of medicines to treat autoimmune and inflammatory conditions	$50.3M	Venrock, Alta Partners & 1 others	57/100